San Diego, CA, United States of America

Qing Dong

USPTO Granted Patents = 67 

 

 

Average Co-Inventor Count = 3.8

ph-index = 8

Forward Citations = 319(Granted Patents)

DiyaCoin DiyaCoin 0.62 


Inventors with similar research interests:


Location History:

  • Jiangsu, CN (2013 - 2016)
  • Morris Plains, NJ (US) (2020)
  • Shanghai, CN (2013 - 2021)
  • San Diego, CA (US) (2009 - 2024)
  • San Francisco, CA (US) (2023 - 2024)

Company Filing History:

goldMedal20 out of 1,177 
 
Takeda Pharmaceutical Company Limited
 patents
silverMedal15 out of 159 
 
Jiangsu Hengrui Medicine Company Ltd.
 patents
bronzeMedal15 out of 100 
 
Shanghai Hengrui Pharmaceutical Co., Ltd.
 patents
411 out of 11 
 
Xinthera, Inc.
 patents
54 out of 4 
 
Alumis Inc.
 patents
63 out of 3,923 
 
Novartis Ag
 patents
72 out of 2 
 
Xizang Haisco Pharmaceutical Co., Ltd.
 patents
82 out of 8 
 
Sichuan Haisco Pharmaceutical Co., Ltd.
 patents
92 out of 2 
 
Fronthera U.S. Pharmaceuticals LLC
 patents
101 out of 1 
 
Esker Therapeutics, Inc.
 patent
111 out of 10 
 
Jiangsu Hansoh Pharmaceutical Co., Ltd.
 patents
121 out of 3 
 
Chengdu Easton Biopharmaceuticals Co., Ltd
 patents
131 out of 2 
 
Triad Liquidating Company, LLC
 patents
141 out of 53 
 
Takeda San Diego, Inc.
 patents
151 out of 3 
 
Takeda Pharmaceutical Company Limied
 patents
161 out of 1 
 
Raythera, Inc.
 patent
171 out of 832,680 
Other
 patents
where one patent can have more than one assignee

Years Active: 2009-2025

where 'Filed Patents' based on already Granted Patents

67 patents (USPTO):

Title: The Innovative Mind of Qing Dong: Pioneering Therapeutic Solutions

Introduction

Qing Dong, based in San Diego, California, is a prolific inventor with an impressive portfolio of 58 patents. His work primarily focuses on the pharmaceutical field, addressing critical health issues through innovative drug development. His inventions are instrumental in paving the way for new treatments in various medical conditions.

Latest Patents

Among his latest contributions to the field are notable inventions such as "Pyridinone MK2 inhibitors and uses thereof." This patent describes MK2 inhibitors and pharmaceutical compositions that are useful for treating autoimmune, chronic, acute, auto-inflammatory, fibrotic, metabolic, neoplastic, and cardiovascular disorders. Another significant patent is for "Substituted pyridines as PARP1 inhibitors," detailing tricyclic PARP1 inhibitors that provide potential cancer treatments.

Career Highlights

Throughout his career, Qing Dong has made substantial contributions while working with esteemed companies such as Takeda Pharmaceutical Company Limited and Jiangsu Hengrui Medicine Company Ltd. His expertise in drug development has established him as a key figure in advancing pharmaceutical research.

Collaborations

Qing Dong’s innovative journey has been complemented by his collaborations with respected colleagues, including Stephen W Kaldor and Piaoyang Sun. These partnerships have fostered a productive environment for scientific exploration and the sharing of knowledge, further enhancing the impact of their collective work.

Conclusion

Qing Dong's dedication to innovation in the pharmaceutical sector has led to the development of groundbreaking therapeutic solutions. With a remarkable collection of patents, his work continues to influence the treatment landscape for various diseases, showcasing the importance of innovation in advancing healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…